Total Payments
$794,158
2024 Payments
$7,744
Companies
22
Transactions
591
Payment Breakdown by Category
Other$341,333 (43.0%)
Consulting$284,993 (35.9%)
Travel$118,582 (14.9%)
Research$33,257 (4.2%)
Food & Beverage$14,832 (1.9%)
Education$1,161 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $321,909 | 157 | 40.5% |
| Consulting Fee | $284,993 | 72 | 35.9% |
| Travel and Lodging | $118,582 | 135 | 14.9% |
| Unspecified | $33,257 | 26 | 4.2% |
| Grant | $16,974 | 16 | 2.1% |
| Food and Beverage | $14,832 | 181 | 1.9% |
| Honoraria | $2,450 | 1 | 0.3% |
| Education | $1,161 | 3 | 0.1% |
Payments by Type
General
$760,901
565 transactions
Research
$33,257
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $232,665 | 159 | $0 (2024) |
| F. Hoffmann-La Roche AG | $161,259 | 113 | $0 (2022) |
| Shire North American Group Inc | $125,212 | 131 | $0 (2019) |
| Hoffmann-La Roche Limited | $77,975 | 17 | $0 (2020) |
| BioMarin Pharmaceutical Inc. | $29,550 | 28 | $0 (2021) |
| Novo Nordisk Inc | $29,176 | 29 | $0 (2021) |
| GENZYME CORPORATION | $23,537 | 9 | $0 (2021) |
| PFIZER INC. | $21,071 | 25 | $0 (2021) |
| BIOVERATIV THERAPEUTICS INC. | $16,712 | 19 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $15,615 | 10 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,744 | 7 | Genentech USA, Inc. ($7,744) |
| 2023 | $7,782 | 4 | Genentech USA, Inc. ($7,782) |
| 2022 | $17,394 | 16 | Genentech USA, Inc. ($14,043) |
| 2021 | $71,179 | 62 | Genentech USA, Inc. ($17,835) |
| 2020 | $106,596 | 56 | F. Hoffmann-La Roche AG ($34,912) |
| 2019 | $196,717 | 135 | Genentech USA, Inc. ($57,380) |
| 2018 | $233,332 | 150 | Genentech USA, Inc. ($81,152) |
| 2017 | $153,413 | 161 | Shire North American Group Inc ($64,738) |
All Payment Transactions
591 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/06/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Consulting Fee | Cash or cash equivalent | $6,460.00 | General |
| Category: Hematology | ||||||
| 09/06/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Travel and Lodging | In-kind items and services | $474.14 | General |
| Category: Hematology | ||||||
| 09/06/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Travel and Lodging | In-kind items and services | $270.86 | General |
| Category: Hematology | ||||||
| 09/06/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Food and Beverage | In-kind items and services | $170.20 | General |
| Category: Hematology | ||||||
| 09/06/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Food and Beverage | In-kind items and services | $152.43 | General |
| Category: Hematology | ||||||
| 09/06/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Food and Beverage | In-kind items and services | $115.60 | General |
| Category: Hematology | ||||||
| 09/05/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Food and Beverage | In-kind items and services | $100.72 | General |
| Category: Hematology | ||||||
| 10/05/2023 | Genentech USA, Inc. | Hemlibra (Biological) | Consulting Fee | Cash or cash equivalent | $6,460.00 | General |
| Category: Hematology | ||||||
| 10/05/2023 | Genentech USA, Inc. | Hemlibra (Biological) | Travel and Lodging | Cash or cash equivalent | $899.74 | General |
| Category: Hematology | ||||||
| 10/05/2023 | Genentech USA, Inc. | Hemlibra (Biological) | Travel and Lodging | Cash or cash equivalent | $354.92 | General |
| Category: Hematology | ||||||
| 06/27/2023 | Genentech USA, Inc. | Hemlibra (Biological) | Food and Beverage | In-kind items and services | $67.65 | General |
| Category: Hematology | ||||||
| 12/31/2022 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $353.86 | Research |
| Study: AN ADAPTIVE PHASE 2A STUDY OF CROVALIMAB IN THE PREVENTION OF ACUTE VASO-OCCLUSIVE CRISIS IN SICKLE CELL DISEASE | ||||||
| 12/31/2022 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $350.95 | Research |
| Study: A PHASE 1B STUDY OF CROVALIMAB IN MANAGEMENT OF ACUTE VOC IN SICKLE CELL DISEASE | ||||||
| 12/31/2022 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $324.84 | Research |
| Study: A PHASE 1B STUDY OF CROVALIMAB IN MANAGEMENT OF ACUTE VOC IN SICKLE CELL DISEASE | ||||||
| 09/30/2022 | F. Hoffmann-La Roche AG | HEMLIBRA (Biological) | — | In-kind items and services | $1,259.23 | Research |
| Study: A MULTICENTER, NON-INTERVENTIONAL STUDY EVALUATING BLEEDING INCIDENCE, HEALTH-RELATED QUALITY OF LIFE, AND SAFETY IN PATIENTS WITH HEMOPHILIA A UNDER STANDARD-OF-CARE TREATMENT • Category: Hematology | ||||||
| 09/23/2022 | Genentech USA, Inc. | HEMLIBRA (Biological) | Food and Beverage | In-kind items and services | $165.62 | General |
| Category: Hematology | ||||||
| 09/22/2022 | Genentech USA, Inc. | HEMLIBRA (Biological) | Consulting Fee | Cash or cash equivalent | $6,460.00 | General |
| Category: Hematology | ||||||
| 09/22/2022 | Genentech USA, Inc. | HEMLIBRA (Biological) | Travel and Lodging | In-kind items and services | $530.21 | General |
| Category: Hematology | ||||||
| 09/22/2022 | Genentech USA, Inc. | HEMLIBRA (Biological) | Travel and Lodging | In-kind items and services | $408.78 | General |
| Category: Hematology | ||||||
| 09/22/2022 | Genentech USA, Inc. | HEMLIBRA (Biological) | Food and Beverage | In-kind items and services | $165.62 | General |
| Category: Hematology | ||||||
| 09/22/2022 | Genentech USA, Inc. | HEMLIBRA (Biological) | Travel and Lodging | Cash or cash equivalent | $69.91 | General |
| Category: Hematology | ||||||
| 09/22/2022 | Genentech USA, Inc. | HEMLIBRA (Biological) | Travel and Lodging | Cash or cash equivalent | $52.00 | General |
| Category: Hematology | ||||||
| 09/02/2022 | Genentech USA, Inc. | HEMLIBRA (Biological) | Travel and Lodging | Cash or cash equivalent | $3,300.00 | General |
| Category: BioOncology | ||||||
| 09/02/2022 | Genentech USA, Inc. | HEMLIBRA (Biological) | Consulting Fee | Cash or cash equivalent | $2,640.00 | General |
| Category: BioOncology | ||||||
| 03/31/2022 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $556.38 | Research |
| Study: AN ADAPTIVE PHASE 2A STUDY OF CROVALIMAB IN THE PREVENTION OF ACUTE VASO-OCCLUSIVE CRISIS IN SICKLE CELL DISEASE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH INHIBITORS. | F. Hoffmann-La Roche AG | $9,448 | 2 |
| A MULTICENTER, NON-INTERVENTIONAL STUDY EVALUATING BLEEDING INCIDENCE, HEALTH-RELATED QUALITY OF LIFE, AND SAFETY IN PATIENTS WITH HEMOPHILIA A UNDER STANDARD-OF-CARE TREATMENT | F. Hoffmann-La Roche AG | $7,560 | 4 |
| Phase 3 Open Label Evaluating RO5534262 in Patients without Inhibitors | F. Hoffmann-La Roche AG | $3,325 | 1 |
| AN ADAPTIVE PHASE 2A STUDY OF CROVALIMAB IN THE PREVENTION OF ACUTE VASO-OCCLUSIVE CRISIS IN SICKLE CELL DISEASE | F. Hoffmann-La Roche AG | $3,311 | 4 |
| A PHASE 1B STUDY OF CROVALIMAB IN MANAGEMENT OF ACUTE VOC IN SICKLE CELL DISEASE | F. Hoffmann-La Roche AG | $3,309 | 5 |
| Phase 3 Open Label Evaluating RO5534262 in Patients without Inhibitors, Phase 3 emicizumab Q4W in patients with hemophilia A, Phase III Inhibitor Study and Open Label Phase III Study of emicizumab in Hemophilia A Pediatrics Patients with Inhibitors | F. Hoffmann-La Roche AG | $3,163 | 4 |
| RIVIPANSEL CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,400 | 1 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS | F. Hoffmann-La Roche AG | $711.66 | 2 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH INHIBITORS., A SINGLE-ARM, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ONCE WEEKLY SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITORS, A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL | F. Hoffmann-La Roche AG | $683.27 | 2 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH INHIBITORS., A SINGLE-ARM, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ONCE WEEKLY SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITORS, A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRI | F. Hoffmann-La Roche AG | $344.96 | 1 |
About Dr. Michael Callaghan, M.D
Dr. Michael Callaghan, M.D is a Pediatric Hematology-Oncology healthcare provider based in Detroit, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1285843672.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Callaghan, M.D has received a total of $794,158 in payments from pharmaceutical and medical device companies, with $7,744 received in 2024. These payments were reported across 591 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($321,909).
Ad
Practice Information
- Specialty Pediatric Hematology-Oncology
- Location Detroit, MI
- Active Since 05/22/2007
- Last Updated 07/08/2007
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1285843672
Products in Payments
- HEMLIBRA (Biological) $237,976
- ADVATE (Biological) $90,810
- Non-Covered Product (Drug) $68,583
- Hemlibra (Biological) $32,858
- NO PRODUCT DISCUSSED (Drug) $19,527
- BENEFIX (Biological) $14,394
- OXBRYTA (Drug) $12,003
- REBINYN (Drug) $9,518
- Kovaltry (Drug) $9,159
- OBIZUR (Biological) $7,230
- FEIBA (Biological) $4,800
- Kogenate FS (Drug) $1,716
- NovoSeven RT (Drug) $1,360
- Alphanate (Biological) $1,262
- XYNTHA (Biological) $724.58
- LYRICA (Drug) $350.00
- RhoGAM Ultra-Filtered PLUS (Biological) $124.27
- Endari (Drug) $109.55
- ADYNOVATE (Biological) $101.87
- Eloctate (Drug) $51.55
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Detroit
Brian Berman, Md, MD
Pediatric Hematology-Oncology — Payments: $28,046
Pediatric Hematology-Oncology $28,046
Dr. Gianna Valenti, Md, MD
Pediatric Hematology-Oncology — Payments: $1,964
Pediatric Hematology-Oncology $1,964
Bulent Ozgonenel, M.d, M.D
Pediatric Hematology-Oncology — Payments: $744.24
Pediatric Hematology-Oncology $744.24
Aghiad Chamdin, Md, MD
Pediatric Hematology-Oncology — Payments: $503.52
Pediatric Hematology-Oncology $503.52
Sarah Ramiz, M.d, M.D
Pediatric Hematology-Oncology — Payments: $361.82
Pediatric Hematology-Oncology $361.82
Rasha Mohammed I Deebajah, Md, MD
Pediatric Hematology-Oncology — Payments: $21.92
Pediatric Hematology-Oncology $21.92